Fas Ligand/TNFSF6 Antibody (100419) [Unconjugated]

In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050), Recombinant Human Fas Ligand/TNFSF6 (Catalog # 126-FL) induces cytotoxicity in the Jurkat human acute T cell leukemia cell line in a dose-dependent manner (orange line). Under these conditions, cytotoxicity elicited by Recombinant Human Fas Ligand/TNFSF6 (2 ng/mL) is neutralized (green line) by increasing concentrations of Human Fas Ligand/TNFSF6 Monoclonal Antibody (Catalog # MAB126). The ND50 is typically 1-5 ng/mL.

• Reactivity: Hu
• Applications: B/N, ELISA(Cap)
• Clone: 100419
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

Fas Ligand/TNFSF6 Antibody (100419) [Unconjugated] Summary

• Immunogen: Chinese hamster ovary cell line CHO-derived recombinant human Fas Ligand/TNFSF6
  Pro134-Leu281
  Accession # P48023
• Specificity: Detects human Fas Ligand/TNFSF6 in ELISAs.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: FASLG
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • Neutralization 1-5 ng/mL
  • ELISA Standard (Matched Pair)
• Application Notes: ELISA Capture: Human Fas Ligand/TNFSF6 Antibody (Catalog # MAB126)
  ELISA Detection: Human Fas Ligand/TNFSF6 Biotinylated Antibody (Catalog # BAF126)
  Standard: Recombinant Human Fas Ligand/TNFSF6 (Catalog # 126-FL)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Fas Ligand/TNFSF6 Antibody (100419) [Unconjugated]

• apoptosis (APO-1) antigen ligand 1
• Apoptosis antigen ligand
• APT1LG1CD95L
• APTL
• CD178 antigen
• CD178
• CD95L
• CD95-L
• Fas antigen ligand
• Fas ligand (TNF superfamily, member 6)
• Fas Ligand
• FASLCD95 ligand
• FASLG
• TNFSF6
• TNFSF6FasL
• tumor necrosis factor (ligand) superfamily, member 6
• tumor necrosis factor ligand superfamily member 6

Background

Fas Ligand (FasL), also known as CD178, CD95L, or TNFSF6, is a 40 kDa type II transmembrane member of the TNF superfamily of proteins. Its ability to induce apoptosis in target cells plays an important role in the development, homeostasis, and function of the immune system (1). Mature human Fas Ligand consists of a 179 amino acid (aa) extracellular domain (ECD), a 22 aa transmembrane segment, and a 80 aa cytoplasmic domain (2). Within the ECD, human Fas Ligand shares 81% and 78% aa sequence identity with mouse and rat Fas Ligand, respectively. Both mouse and human Fas Ligand are active on mouse and human cells (2, 3). Fas Ligand is expressed on the cell surface as a nondisulfide-linked homotrimer on activated CD4+ Th1 cells, CD8+ cytotoxic T cells, and NK cells (1). Fas Ligand binding to Fas/CD95 on an adjacent cell triggers apoptosis in the Fas‑expressing cell (2, 4). Fas Ligand also binds DcR3 which is a soluble decoy receptor that interferes with Fas Ligand-induced apoptosis (5). Fas Ligand can be released from the cell surface by metalloproteinases as a 26 kDa soluble molecule which remains trimeric (6, 7). Shed Fas Ligand retains the ability to bind Fas, although its ability to trigger apoptosis is dramatically reduced (6, 7). In the absence of TGF‑ beta, however, Fas Ligand/Fas interactions instead promote neutrophil-mediated inflammatory responses (3, 8). Fas Ligand itself transmits reverse signals that costimulate the proliferation of freshly antigen-stimulated T cells (9). Fas Ligand-induced apoptosis plays a central role in the development of immune tolerance and the maintance of immune privileged sites (10). This function is exploited by tumor cells which evade immune surveillance by upregulating Fas Ligand to kill tumor infiltrating lymphocytes (8, 11). In gld mice, a Fas Ligand point mutation is the cause of severe lymphoproliferation and systemic autoimmunity (12, 13).

1. Lettau, M. et al. (2008) Curr. Med. Chem. 15:1684.
2. Takahashi, T. et al. (1994) Int. Immunol. 6:1567.
3. Seino, K-I. et al. (1998) J. Immunol. 161:4484.
4. Suda, T. et al. (1993) Cell 75:1169.
5. Pitti, R.M. et al. (1998) Nature 396:699.
6. Schneider, P. et al. (1998) J. Exp. Med. 187:1205.
7. Tanaka, M. et al. (1998) Nature Med. 4:31.
8. Chen, J-J. et al. (1998) Science 282:1714.
9. Suzuki, I. and P.J. Fink (2000) Proc. Natl. Acad. Sci. USA 97:1707.
10. Ferguson, T.A. and T.S. Griffith (2006) Immunol. Rev. 213:228.
11. Ryan, A.E. et al. (2005) Cancer Res. 65:9817.
12. Takahashi, T. et al. (1994) Cell 76:969.
13. Lynch, D.H. et al. (1994) Immunity 1:131.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Fas Ligand/TNFSF6 Antibody (MAB126)(12)

Publications using MAB126

• M Idelson, R Alper, A Obolensky, N Yachimovic, J Rachmilewi, A Ejzenberg, E Beider, E Banin, B Reubinoff Immunological Properties of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Stem Cell Reports, 2018;0(0):. 2018 [PMID: 30122442] (Neutralization, Human)
• M Kim, S Pyo, CH Kang, CO Lee, HK Lee, SU Choi, CH Park Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer PLoS ONE, 2018;13(6):e0198347. 2018 [PMID: 29874279] (Neutralization, Human)
• S Nakachi, S Sumitomo, Y Tsuchida, H Tsuchiya, M Kono, R Kato, K Sakurai, N Hanata, Y Nagafuchi, S Tateishi, H Kanda, T Okamura, K Yamamoto, K Fujio Interleukin-10-producing LAG3(+) regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis Arthritis Res. Ther., 2017;19(1):97. 2017 [PMID: 28511719] (Neutralization, Human)
• N Köstlin, M Vogelmann, B Spring, J Schwarz, J Feucht, C Härtel, TW Orlikowsky, CF Poets, C Gille Granulocytic myeloid derived suppressor cells from human cord blood modulate T-helper-cell response towards an anti-inflammatory phenotype Immunology, 2017;0(0):. 2017 [PMID: 28464218] (Neutralization, Human)
• MC Tanzer, N Khan, JA Rickard, N Etemadi, N Lalaoui, SK Spall, JM Hildebrand, D Segal, M Miasari, D Chau, WL Wong, M McKinlay, SK Chunduru, CA Benetatos, SM Condon, JE Vince, MJ Herold, J Silke Combination of IAP antagonist and IFN? activates novel caspase-10- and RIPK1-dependent cell death pathways Cell Death Differ, 2017;0(0):. 2017 [PMID: 28106882] (Neutralization, Human)
• ME Guicciardi, A Krishnan, SF Bronk, P Hirsova, TS Griffith, GJ Gores Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice Cell Death Dis, 2017;8(1):e2535. 2017 [PMID: 28055006] (Neutralization, Human)
• Zheng J, Wu W, Liu Y, Xiang Z, Liu M, Chan K, Lau S, Lam K, To K, Chan J, Li L, Chen H, Lau Y, Yuen K, Tu W The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice. PLoS ONE, 2015;10(8):e0135999. 2015 [PMID: 26285203] (Neutralization, Human)
• Yang, Kai-Lin, Wang, Yu-Shan, Chang, Chao-Chu, Huang, Su-Chen, Huang, Yi-Chun, Chi, Mau-Shin, Chi, Kwan-Hwa Reciprocal complementation of the tumoricidal effects of radiation and natural killer cells. PLoS ONE, 2013;8(4):e61797. 2013 [PMID: 23634213] (Neutralization, Human)
• Inoue T, Tashiro Y, Takeuchi M Potent anti-tumor killing activity of the multifunctional Treg cell line HOZOT against human tumors with diverse origins. Int. J. Oncol., 2011;38(5):1299-306. 2011 [PMID: 21373756] (Neutralization, Human)
• Navenot JM, Fujii N, Peiper SC KiSS1 metastasis suppressor gene product induces suppression of tyrosine kinase receptor signaling to Akt, tumor necrosis factor family ligand expression, and apoptosis. Mol. Pharmacol., 2009;75(5):1074-83. 2009 [PMID: 19201817] (Neutralization, Human)
• Krysov SV, Krysov&lt;/LastName&gt;&lt;ForeNam SV&lt;/Initia, Rowley TF, Al-Shamkhani A Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells. Mol. Cancer Ther., 2007;6(2):703-11. 2007 [PMID: 17308066] (Neutralization, Human)
• Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ., 2006;13(10):1789-801. 2006 [PMID: 16429118] (Neutralization, Human)

Bioinformatics

• Gene Symbol: FASLG
• Uniprot:
  • P48023()